EAST HANOVER, N.J., Sept. 13, 2017 /PRNewswire/ -- Novartis announced today first of its kind Phase III data showing Cosentyx ® (secukinumab) delivered high and long-lasting skin clearance in patients ...

Cosentyx (secukinumab) is a prescription drug that’s used to treat conditions such as plaque psoriasis and psoriatic arthritis. Cosentyx is given as an injection under the skin or as an IV infusion.

Cosentyx (secukinumab) is a brand-name injection prescribed for plaque psoriasis and certain types of arthritis. It works to treat these conditions by slowing down an overactive immune system.

The Food and Drug Administration (FDA) has approved Cosentyx (secukinumab) injections for treating various inflammatory conditions in adults and, in some cases, children. Cosentyx may treat moderate ...

Cosentyx, an autoimmune disease therapy that cost the healthcare industry $7.7 billion in 2024, will be offered at a 55% discount beginning in November. The drug’s manufacturer, Novartis, said Sept.

Please provide your email address to receive an email when new articles are posted on . This approval makes Cosentyx the first interleukin-17A inhibitor and second biologic approved for hidradenitis ...

Novartis today announced new two-year results demonstrating sustained efficacy with Cosentyx™ (secukinumab) with an acceptable safety profile for the treatment of psoriasis patients. The data comes ...

Please provide your email address to receive an email when new articles are posted on . Based on the recommendation, the European Commission will make a final decision within 2 months. If approved, ...

The approval was based on data from the 2-year phase 3 JUNIPERA study that evaluated secukinumab in pediatric patients aged 2 to 17 years with a confirmed diagnosis of ERA or JPsA. The Food and Drug ...

Common side effects of Cosentyx (secukinumab) include diarrhea, headache, and upper respiratory tract infections. Serious side effects of Cosentyx can include infections such as tuberculosis and ...

cosentyx article Cosentyx is the first and only fully-human interleukin-17A (IL-17A) antagonist. In the SCALP study, patients with moderate to severe psoriasis lesions of the scalp (n=102) were ...